InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

Current share price for LTP : $0.505 0.005 (0.98%)+

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$92 LTR Executes U.S. Commercial Agreement with Strive 20 Jul 2026 8:55AM $0.510 $0.505 fallen by 0.98%
$92 LTR Executes Definitive U.S. Commercial Agreement with Shed 17 Jul 2026 8:48AM $0.495 $0.505 risen by 2.02%
$92 Notification regarding unquoted securities - LTP 10 Jul 2026 4:28PM $0.520 $0.505 fallen by 2.88%
$92 OROFLOW Clinical Study Receives Ethics Approval 24 Jun 2026 8:22AM $0.565 $0.505 fallen by 10.62%
$92 Response to ASX Aware Letter 15 Jun 2026 2:16PM $0.505 $0.505 fallen by 0%
$92 LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS 11 Jun 2026 8:38AM $0.425 $0.505 risen by 18.82%
$92 LTR Secures First U.S. Commercial Agreement for ROXUS 9 Jun 2026 8:35AM $0.465 $0.505 risen by 8.60%
$92 Investor Presentation 1 May 2026 9:19AM $0.405 $0.505 risen by 24.69%
$92 SPONTAN Phase II data show rapid onset, support FDA pathway 1 May 2026 9:18AM $0.405 $0.505 risen by 24.69%
$92 Trading Halt 29 Apr 2026 8:29AM $0.405 $0.505 risen by 24.69%
$92 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 8:52AM $0.430 $0.505 risen by 17.44%
$92 Investor Presentation 11 Mar 2026 8:40AM $0.460 $0.505 risen by 9.78%
$92 SPONTAN Phase II Clinical Study Completes Recruitment 5 Mar 2026 8:31AM $0.430 $0.505 risen by 17.44%
$92 Appendix 4D and Half Yearly Report 26 Feb 2026 8:12AM $0.490 $0.505 risen by 3.06%
$92 Application for quotation of securities - LTP 10 Feb 2026 12:20PM $0.535 $0.505 fallen by 5.61%
$92 SPONTAN Shows Positive Outcomes in Younger Men with ED 2 Feb 2026 8:46AM $0.545 $0.505 fallen by 7.34%
$92 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:27AM $0.585 $0.505 fallen by 13.68%
$92 First Patients Dosed in SPONTAN Phase II Clinical Study 22 Jan 2026 8:52AM $0.570 $0.505 fallen by 11.40%
$92 Application for quotation of securities - LTP 21 Jan 2026 3:35PM $0.550 $0.505 fallen by 8.18%
$92 Notification regarding unquoted securities - LTP 16 Jan 2026 4:58PM $0.575 $0.505 fallen by 12.17%
$92 Patient Recruitment Commences for SPONTAN Phase II Study 13 Jan 2026 8:23AM $0.640 $0.505 fallen by 21.09%
$92 SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium 8 Jan 2026 9:14AM $0.630 $0.505 fallen by 19.84%
$92 Notification regarding unquoted securities - LTP 22 Dec 2025 5:03PM $0.540 $0.505 fallen by 6.48%
$92 LTR Pharma Surpasses 1,000 SPONTAN Prescriptions 17 Dec 2025 9:12AM $0.465 $0.505 risen by 8.60%
$92 Application for quotation of securities - LTP 11 Dec 2025 9:45AM $0.480 $0.505 risen by 5.21%

1 - 25 of 138 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.